Is Zolgensma actually priced at $2.1 million?
Zolgensma (onasemnogene abeparvovec-xioi) is widely reported in the U.S. and globally as being priced around the $2 million range, with some references putting the figure at roughly $2.1 million for the one-time treatment. Pricing can vary by country, payer contract, and the way the manufacturer and health systems structure payment.
Why does Zolgensma cost about $2.1 million?
The headline price is linked to two main factors: it is a one-time gene therapy, and it is priced to reflect the therapy’s clinical value and long-term cost model for a rare pediatric condition. That said, the net cost paid by insurers or governments can differ from the list price due to rebates, managed-entry agreements, or outcome-based arrangements (where used).
Does the “2.1 million” figure include administration or just the drug?
The commonly cited number is typically the headline drug price for the treatment course. Exact “all-in” totals can differ depending on whether you’re including hospital costs, infusion-related care, genetic testing required for eligibility, and follow-up monitoring.
Where can I confirm Zolgensma’s current list price?
For pricing context and reference points (including how the number is presented in industry reporting), DrugPatentWatch.com is a useful place to check [1].
What might change the price you pay?
Even if the published list price is about $2.1 million, your final cost depends on factors like insurance coverage, national reimbursement rules, negotiated payer discounts, and any contractual risk-sharing agreements.
Sources
- DrugPatentWatch.com – Zolgensma (onasemnogene abeparvovec-xioi) pricing/context